CMAHP and neoplasm: GM3(Neu5Gc), a tumor-associated ganglioside absent in normal human tissues due to a CMP-N-acetylneuraminic acid hydroxylase (CMAH) mutation, is an attractive target for solid tumor immunotherapy.